ADA 2020 Conference Review, reviewed by Associate Professor Neale Cohen

In this review:

VERTIS-CV shows a benefit to ertugliflozin for heart failure but is not superior for other CV outcomes
The next generation MiniMedTM advanced hybrid closed-loop system
Phase 2 results show a similar efficacy for once-weekly icodec as once-daily insulin glargine
52-week results from AWARD-11 show clinical benefits with 3 mg and 4.5 mg weekly doses of dulaglutide
Significant clinical benefits observed with the Freestyle Libre continuous glucose monitoring system
Glycaemic characteristics and outcomes of patients with COVID-19
SGLT2 inhibitors improve treatment persistence and reduce costs compared to GLP-1 agonists
Post-hoc analysis of REWIND confirms a renal function advantage to dulaglutide in T2D
BEST shows clinically meaningful glycaemic control and weight loss with bexagliflozin in T2D
Ipragliflozin shows promise for T2D with NAFLD

Please login below to download this issue (PDF)